DMS International

DMS Group (Diagnostic Medical Systems) is a French healthcare company specializing in high-tech medical imaging and biotechnologies. Through its DMS Biotech division, the company focuses on regenerative medicine, particularly the development of adipose-derived stem cell (ADSC) therapies for treating osteoarthritis and other inflammatory conditions. Its lead biotech program, Hy-G-Cell, utilizes a proprietary kit for the preparation of autologous adipose tissue grafts to promote joint repair. The company is publicly traded on Euronext Growth Paris and maintains a global presence through its imaging subsidiary, Apelem, which specializes in digital radiology and bone densitometry.